The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients with more than one post-resistant biopsy.
Zofia Piotrowska
No relevant relationships to disclose
Matthew J. Niederst
No relevant relationships to disclose
Mari Mino-Kenudson
No relevant relationships to disclose
Vicente Morales-Oyarvide
No relevant relationships to disclose
Linnea Fulton
No relevant relationships to disclose
Elizabeth L. Lockerman
No relevant relationships to disclose
Emily Howe
No relevant relationships to disclose
Justin F. Gainor
No relevant relationships to disclose
Panos Fidias
No relevant relationships to disclose
Subba Digumarthy
No relevant relationships to disclose
Rebecca Suk Heist
No relevant relationships to disclose
Alice Tsang Shaw
Consultant or Advisory Role - ARIAD; Chugai Pharma; Daiichi Sankyo; Genentech; Novartis; Pfizer
Jeffrey A. Engelman
Consultant or Advisory Role - AstraZeneca; GATEKEEPER Pharmaceuticals; Genentech; Novartis
Stock Ownership - GATEKEEPER Pharmaceuticals
Honoraria - AstraZeneca; Genentech; Novartis
Research Funding - Amgen; AstraZeneca; Novartis; Sanofi
Other Remuneration - AstraZeneca; GATEKEEPER Pharmaceuticals; Genentech; Novartis
Lecia V. Sequist
Consultant or Advisory Role - AstraZeneca (U); Boehringer Ingelheim (U); Clovis (U); Merrimack Pharmaceuticals (U)